By Katherine Hamilton
Masimo forecast a stronger than expected 2025 as it refocuses on its core medical business.
In its fourth-quarter earnings report, the medical technology maker guided for adjusted earnings per share of $5.10 to $5.40 in 2025, ahead of the $4.69 a share analysts polled by FactSet were expecting. It expects healthcare revenue to be $1.50 million to $1.53 million this year, which would be an 8% to 11% increase.
Masimo posted a fourth-quarter loss of $349.6 million, or $6.52 a share, in the three months ended Dec. 28, compared with a profit of $34 million, or 63 cents a share, a year earlier.
Stripping out certain one-time items, adjusted per-share earnings were $1.80, ahead of the $1.43 forecast by analysts, according to FactSet.
Revenue rose 9%, to $600.7 million. Analysts surveyed by FactSet forecast revenue of $593 million.
Masimo is currently undergoing a strategic realignment to focus on its core healthcare business. In January, the Irvine, Calif., company named Katie Szyman, who was head of patient monitoring at Becton Dickinson and Co., as its new chief executive.
"As a result of our strategic realignment efforts in the fourth quarter, we expect to see increased earnings and cash flow in 2025 and beyond," Szyman said.
Operating expenses more than doubled compared with the previous year, contributing to the overall loss.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
February 25, 2025 16:45 ET (21:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.